{
    "nctId": "NCT05417867",
    "briefTitle": "Association Between Changes in the Gut Microbiome and Chemotherapy-Induced Nausea in Stage I-III Breast Cancer",
    "officialTitle": "A Pilot Study of the Associations Between Chemotherapy-Induced Nausea in Breast Cancer Patients and Gut Microbiome Composition Profiles",
    "overallStatus": "RECRUITING",
    "conditions": "Chemotherapy-Related Nausea and/or Vomiting, Early Stage Breast Carcinoma",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 50,
    "primaryOutcomeMeasure": "Number of patients approached",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects with a diagnosis of early stage breast cancer, planning to receive moderate to highly emetogenic chemotherapy will be recruited at Mayo Clinic, Arizona and Mayo Clinic Florida\n* At least 20 years of age\n* Last chemotherapy more than 3 years ago\n* Scheduled to receive moderate to highly emetogenic chemotherapy with or without targeted therapies including immunotherapies\n\nExclusion Criteria:\n\n* Metastatic disease\n* Concurrent radiation therapy\n* Concurrent antibiotic treatment",
    "sex": "ALL",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}